DAFTAR PUSTAKA

1. LaBrecque DR. Mass Lesions & Neoplasia of the Liver. .Friedman LS, McQuaid KR, Grendell JH, editor. Current Diagnosis & Treatment in Gastroenterology. Singapore: McGraw-Hill Education. 2003.
2. Saxena R. Practical hepatic Pathology : A Diagnostic Approach. Philadelphia: Elsevier Saunders. 2011.
3. Murray-Lyon IM. Primary and secondary cancer of the liver. Gazet JC, editor. Carcinoma of the Liver, Biliary Tract and Pancreas. London: Edward Arnold. 1983.
4. Sherlock S, Dooley J. Disease of the Liver and Biliary System. London: Blackwell Scientific Publications. 1993.
5. Hirlan. Karsinoma Hepatoseluler (KHS). Hirlan, Purnomo HD, editor. Semarang Gastroenterohepatology Update 2011 Current Issues in Gastroenterohepatologi: From Theory to Clinical Practice. Semarang: Badan Penerbit Universitas Diponegoro. 2011.
6. Minshan C, Yaqi Z. Karsinoma Hati Primer. Desen W, editor. Buku Ajar Onkologi Klinis Edisi 2. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia. 2008.
7. Sherman M. Hepatocellular Carcinoma: Epidemiology, Screening, and Prevention. Kelsen DP, Daly JM. Kern SE, Levin B, Tepper JE, Cutsem VE, editor. Principles And Practice of Gastrointestinal Oncology. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer business. 2008.

8. Wibowo S, Kanadihardja W, Sjamsuhidajat R, Syukur A. Saluran Empedu dan Hati. Sjamsuhidat R, Karnadihardja W, Prasetyono TOH, Rudiman R, esditor. Buku Ajar Ilmu Bedah Sjamsuhidajat-De Jong, Ed. 3. Jakarta: EGC. 2011.
9. Nurdjanah S. Sirosis Hati. Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Jakarta: InternaPublishing. 2009.
10. Caldwell S, Park SH. The epidemiology of hepatocelullar cancer: from the perspectives of public health problem to tumor biology. Journal of Gastroenterology. 2009;44: 96-100.
11. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. Journal of Gastroenterology. 2009;44: 89-95.
12. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Journal of Gastroenterology. 2009;44: 102-107.
13. Sakamoto M. Early HCC: Diagnosis and molecular markers. Journal of Gastroenterology. 2009;44: 108-110.
14. Kudo M. Multistep human carcinogenesis: correlation of imaging with pathology. Journal of Gastroenterology. 2009;44: 112-116.
15. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353: 1253–7.

16. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39: 486–492.
17. Bertino G, Carlo DI, Ardiri A, Calvagno GS, Demma Shirin, Malaguarnera G, Bertino N, et al. Systemic therapies in hepatocellular carcinoma. Future Oncol [Internet]. 2013;9(10):1533-1548. Available from: http://www.medscape.com/viewarticle/812561_3
18. Saffroy R, Lemoine A, Debuire B. Mechanisms of hepatocarcinogenesis. Atlas of Genetics and Cytogenetics in Oncology and Haematology [Internet]. 2006. Available from: http://atlasgeneticsoncology.org/Deep/HepatocarcinogenesisID20055.html
19. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332: 1463-1466
20. Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms: Hepatocellular Adenoma, hepatocellular Carcinoma, and hepatoblastoma (Eds Coleman WB and Tsongalis GJ). In The Molecular Basis of Human Cancer . 2001; 269-346.
21. Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106: 636-647
22. Sugihara S, Nakashima O, Kojiro M, Majima Y, Tanaka M, Tanikawa K.The morphologic transition in hepatocellular carcinoma: A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer. 1992;70: 1488-1492.

23. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver. 1987;7: 18-26.
24. Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T. Hepatocellular carcinoma presenting as intrabile duct tumor growth: A clinicopathologic study of 24 cases [Internet]. Cancer. 1982;49(10):2144-7. Available from: NCBI
25. Lee NW, Wong KP, Siu KF, Wong J. Cholangiography in hepatocellular carcinoma with obstructive jaundice. Clin Radiol. 1984;35(2):119-23.
26. Ihde DC, Sherlock P, Winawer SJ, Fortner JG. Clinical manifestations of hepatoma: A review of 6 years experience at a cancer hospital. Am J Med. 1974;56(1):83-91
27. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462-503.
28. Sastroasmoro S, Ismael S. Dasar-Dasar Metodologi Penelitian Klinis. Jakarta: Sagung Seto.2011.
29. Miyamoto M, Sudo T, Kuyama T. Spontaneous rupture of hepatocellular carcinoma: A review of 172 Japanese cases. Am J Gastroenterol. 1991;86: 87.
30. Attali P, Houssin D, Roche A, Buffet C, Bismuth H, Etienne JP. Hepatic arterial embolization for malignant hypercalcemia in hepatocellular carcinoma. Dig Dis Sci. 1984;29:466.

31. Hsu Ys, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HbeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35(6):1522-27.
32. Atterbury CE. Neoplasms of The Liver and Biliary Tract. Eastwood GL, editor. Core Textbook of Gastroenterology. Philadelpia: J.B. Lippincott Company. 1984.
33. Nakashima T, Kojiro M. Hepatocellular carcinoma. Tokyo: Springer Verlag. 1987.
34. Iwasaki M, Furuse J, Yoshino M, Ryu M, Moriyama N, Mukai K. Sonographic appearance of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography. J Clin Ultrasound. 1998;26(6):303-7.
35. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography in superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. Hepatology. 2003;38(4):1034-42.
36. Jeong YY, Mitchell DG, Kamishima T. Small (<20mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: Cllinical implications. AJR Am J Roentgenol. 2002;178(6):1327-34.
37. Fracanzani AL, Burdick L, Borzio M, Roncalli M, Bonelli N, Borzio F, et al. Contrast-enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology. 2001;34(6):1109-12.

38. Takayama T, Kosuge T, Yamazaki S, Hasegawa H, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet. 1990;336(8724):1150-3.
39. Compton CC**,** Byrd**,** DR**,** Garcia-Aguilar J**,** Kurtzman SH, Olawaiye A**,** Washington MK**.** AJCC Cancer Staging Atlas Cancer Survival Analysis [Internet]. 2012. Available from : http://www.springer.com/978-1-4614-2079-8.
40. Parkin DM, Hakulinen T. Analysis of Survival. Available from: http://www.iarc.fr/en/publications/pdfs-online/epi/sp95/sp95-chap12.pdf
41. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. British Journal of Cancer. 2005;92:1862-8.
42. Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, et al. Fibrolamellar hepatocellular carcinoma-Prolonged survival with multimodality therapy. European Journal of Surgical Oncology. 2009;35:617-621.
43. Hernández-Castillo E, Mondragón-Sánchez R, Garduno-Lopez AL, Gómez-Gómez E, Ruiz-Molina JM, Oñate-Ocaña LF, et al. Hepatocellular carcinoma in the youth: A comparative analysis with hepatocellular carcinoma in adulthood. Hepato-gastroenterology. 2005; 52(63):903-907.
44. Tirunagari S, Shaik D. Hepato Cellular Carcinoma. WebmedCentral Clinical Trials. 2013;4(3):WMC004083.

45. Liang P, Dong B, Yu X, Yu D, Wang Y, Feng L, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005; 235:299-307.
46. Okonkwo UC, Nwosu MN, Ukah C, Okpala OC, Ahaneku JI. The clinical and pathological features of hepatocellular carcinoma in Nnewi, Nigeria. Niger J Med. 2011 Jul-Sep;20(3):366-71.
47. Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer. 1995;63:491-3.
48. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, et al. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroentero. 2001;7(2):208 – 215.
49. Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A, et al. Etiologic Factors and Clinical Presentation of Hepatocellular Carcinoma Differences between Cirrhotic and Noncirrhotic Italian Patients. Cancer. 1995;75(9):2220-2232.
50. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.
51. Donato F, Boffeta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer. 1998;75:347-354.
52. Davilla JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a

population based case control study. *Gut.* 2005;54:533-539 doi:10.1136/gut.2004.052167.

53. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. Journal of Hepatology. 2012;56:1384–1391.
54. Robin S, Sunil K, Rana AC, Nidhi S. Different models of hepatotoxicity and related liver disease: A review. International Research Journal of Pharmacy. 2012; 3:7.
55. Pratt DS, Kaplan MM. Laboratory Test. Schiff ER, Sorrell MF, Maddrey WC, editor. Schiff's Disease of The Liver, 10th edition, vol. 1. Philadelphia: Lippincot Williams&Wilkins. 2007
56. Law WY. Hepatocellular Carcinoma. Singapore: World Scientific Publishing. 2008.
57. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274-83.
58. Radu P, Ioana G, Iancu C, Al-Hajjar N, Andreica V, Sparchez Z. Treatment of Hepatocellular Carcinoma in a Tertiary Romanian Center. Deviations from BCLC Recommendations and In uence on Survival Rate. J Gastrointestin Liver Dis.2013; 22(3): 291-297.
59. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C Virus related cirrhosis: time to occurence of hepatocellular carcinoma and death. Gut. 2000;47:131-136.

60. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107: 569-577.

LAMPIRAN 1

OUTPUT SPSS

Deskriptif

Umur

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	11 - 20	1	.4	.4	.4
	21 - 30	4	1.7	1.7	2.1
	31 - 40	29	12.3	12.3	14.5
	41 - 50	63	26.8	26.8	41.3
	51 - 60	87	37.0	37.0	78.3
	61 - 70	32	13.6	13.6	91.9
	71 - 80	15	6.4	6.4	98.3
	> 80	4	1.7	1.7	100.0
	Total	235	100.0	100.0	

Case Summaries

Umur

N	Mean	Std. Deviation	Median	Minimum	Maximum
235	52.83	11.775	52.00	17	85

Jenis kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	172	73.2	73.2	73.2
	Perempuan	63	26.8	26.8	100.0
	Total	235	100.0	100.0	

Badan Lemas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	14	6.0	6.0	6.0
	Tidak	221	94.0	94.0	100.0
	Total	235	100.0	100.0	

Mual muntah

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	10	4.3	4.3	4.3
	Tidak	225	95.7	95.7	100.0
	Total	235	100.0	100.0	

Nyeri perut

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	50	21.3	21.3	21.3
	Tidak	185	78.7	78.7	100.0
	Total	235	100.0	100.0	

Perut membesar

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	62	26.4	26.4	26.4
	Tidak	173	73.6	73.6	100.0
	Total	235	100.0	100.0	

Benjolan di perut

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	58	24.7	24.7	24.7
	Tidak	177	75.3	75.3	100.0
	Total	235	100.0	100.0	

Perut sebah

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	11	4.7	4.7	4.7
	Tidak	224	95.3	95.3	100.0
	Total	235	100.0	100.0	

Sesak nafas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	6	2.6	2.6	2.6
	Tidak	229	97.4	97.4	100.0
	Total	235	100.0	100.0	

Lain-lain

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	24	10.2	10.2	10.2
	Tidak	211	89.8	89.8	100.0
	Total	235	100.0	100.0	

Ensefalopati Hepatikum

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	-	205	87.2	87.2	87.2
	Grade I-II	11	4.7	4.7	91.9
	Grade III-IV	19	8.1	8.1	100.0
	Total	235	100.0	100.0	

Ascites

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	-	93	39.6	39.6	39.6
	ringan	31	13.2	13.2	52.8
	sedang	71	30.2	30.2	83.0
	permagna	40	17.0	17.0	100.0
	Total	235	100.0	100.0	

Klasifikasi Child-Pugh

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	A	33	14.0	16.8	16.8
	B	96	40.9	49.0	65.8
	C	67	28.5	34.2	100.0
	Total	196	83.4	100.0	
Missing	System	39	16.6		
Total		235	100.0		

PST

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	0	42	17.9	17.9	17.9
	1	68	28.9	28.9	46.8
	2	55	23.4	23.4	70.2
	3	34	14.5	14.5	84.7
	4	36	15.3	15.3	100.0
	Total	235	100.0	100.0	

BCLC Stage

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	A	3	1.3	1.8	1.8
	B	20	8.5	12.2	14.0
	C	73	31.1	44.5	58.5
	D	68	28.9	41.5	100.0
	Total	164	69.8	100.0	
Missing	System	71	30.2		
Total		235	100.0		

HBV

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	157	66.8	66.8	66.8
	Tidak	78	33.2	33.2	100.0
	Total	235	100.0	100.0	

HCV

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	16	6.8	6.8	6.8
	Tidak	219	93.2	93.2	100.0
	Total	235	100.0	100.0	

Tidak diketahui

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	49	20.9	20.9	20.9
	Tidak	186	79.1	79.1	100.0
	Total	235	100.0	100.0	

DM

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	11	4.7	4.7	4.7
	Tidak	224	95.3	95.3	100.0
	Total	235	100.0	100.0	

NAFLD

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	10	4.3	4.3	4.3
	Tidak	225	95.7	95.7	100.0
	Total	235	100.0	100.0	

Statistics

		Bilirubin Total	Albumin serum	PPT
N	Valid	204	215	196
	Missing	31	20	39
Mean		4.3379	2.724	3.935
Median		1.8600	2.700	2.700
Std. Deviation		6.03845	.6240	5.3246
Minimum		.06	1.1	-.7
Maximum		30.28	4.4	36.6

Survival Kaplan-Meier

Survival Table

	Time	Status	Cumulative Proportion Surviving at the Time		N of Cumulative Events	N of Remaining Cases
			Estimate	Std. Error		
1	1.000	Meninggal	.	.	1	62
2	1.000	Meninggal	.	.	2	61
3	1.000	Meninggal	.	.	3	60
4	1.000	Meninggal	.	.	4	59
5	1.000	Meninggal	.	.	5	58
6	1.000	Meninggal	.	.	6	57
7	1.000	Meninggal	.	.	7	56
8	1.000	Meninggal	.	.	8	55
9	1.000	Meninggal	.	.	9	54
10	1.000	Meninggal	.	.	10	53
11	1.000	Meninggal	.	.	11	52
12	1.000	Meninggal	.	.	12	51
13	1.000	Meninggal	.	.	13	50
14	1.000	Meninggal	.	.	14	49
15	1.000	Meninggal	.	.	15	48
16	1.000	Meninggal	.	.	16	47
17	1.000	Meninggal	.	.	17	46
18	1.000	Meninggal	.	.	18	45
19	1.000	Meninggal	.	.	19	44
20	1.000	Meninggal	.	.	20	43
21	1.000	Meninggal	.	.	21	42
22	1.000	Meninggal	.	.	22	41
23	1.000	Meninggal	.	.	23	40
24	1.000	Meninggal	.	.	24	39
25	1.000	Meninggal	.	.	25	38
26	1.000	Meninggal	.	.	26	37
27	1.000	Meninggal	.	.	27	36
28	1.000	Meninggal	.	.	28	35
29	1.000	Meninggal	.	.	29	34
30	1.000	Meninggal	.	.	30	33
31	1.000	Meninggal	.	.	31	32
32	1.000	Meninggal	.	.	32	31
33	1.000	Meninggal	.	.	33	30
34	1.000	Meninggal	.	.	34	29
35	1.000	Meninggal	.	.	35	28
36	1.000	Meninggal	.	.	36	27
37	1.000	Meninggal	.	.	37	26
38	1.000	Meninggal	.	.	38	25
39	1.000	Meninggal	.	.	39	24
40	1.000	Meninggal	.	.	40	23
41	1.000	Meninggal	.	.	41	22
42	1.000	Meninggal	.333	.059	42	21
43	1.500	Meninggal	.317	.059	43	20
44	2.000	Meninggal	.	.	44	19
45	2.000	Meninggal	.	.	45	18
46	2.000	Meninggal	.	.	46	17
47	2.000	Meninggal	.	.	47	16
48	2.000	Meninggal	.	.	48	15
49	2.000	Meninggal	.	.	49	14
50	2.000	Meninggal	.	.	50	13
51	2.000	Meninggal	.	.	51	12
52	2.000	Meninggal	.	.	52	11
53	2.000	Meninggal	.	.	53	10
54	2.000	Meninggal	.	.	54	9
55	2.000	Meninggal	.	.	55	8
56	2.000	Meninggal	.111	.040	56	7
57	3.000	Meninggal	.	.	57	6
58	3.000	Meninggal	.079	.034	58	5
59	3.500	Meninggal	.063	.031	59	4
60	4.000	Meninggal	.	.	60	3
61	4.000	Meninggal	.032	.022	61	2
62	6.000	Meninggal	.016	.016	62	1
63	12.000	Hidup	.	.	62	0

Case Processing Summary

Total N	N of Events	Censored	
		N	Percent
63	62	1	1.6%

Means and Medians for Survival Time

Mean[a]				Median			
		95% Confidence Interval				95% Confidence Interval	
Estimate	Std. Error	Lower Bound	Upper Bound	Estimate	Std. Error	Lower Bound	Upper Bound
1.667	.203	1.269	2.064	1.000	.	.	.

a. Estimation is limited to the largest survival time if it is censored.



Uji Chi-Square

Survival Rate * BCLC Stage Crosstabulation

			BCLC Stage				
			A	B	C	D	Total
Survival Rate	1	Count	0	1	9	24	34
		Expected Count	.6	1.3	13.5	18.6	34.0
		% within BCLC Stage	.0%	50.0%	42.9%	82.8%	64.2%
		% of Total	.0%	1.9%	17.0%	45.3%	64.2%
	2	Count	0	1	8	4	13
		Expected Count	.2	.5	5.2	7.1	13.0
		% within BCLC Stage	.0%	50.0%	38.1%	13.8%	24.5%
		% of Total	.0%	1.9%	15.1%	7.5%	24.5%
	3	Count	0	0	2	0	2
		Expected Count	.0	.1	.8	1.1	2.0
		% within BCLC Stage	.0%	.0%	9.5%	.0%	3.8%
		% of Total	.0%	.0%	3.8%	.0%	3.8%
	4	Count	0	0	2	0	2
		Expected Count	.0	.1	.8	1.1	2.0
		% within BCLC Stage	.0%	.0%	9.5%	.0%	3.8%
		% of Total	.0%	.0%	3.8%	.0%	3.8%
	6	Count	0	0	0	1	1
		Expected Count	.0	.0	.4	.5	1.0
		% within BCLC Stage	.0%	.0%	.0%	3.4%	1.9%
		% of Total	.0%	.0%	.0%	1.9%	1.9%
	24	Count	1	0	0	0	1
		Expected Count	.0	.0	.4	.5	1.0
		% within BCLC Stage	100.0%	.0%	.0%	.0%	1.9%
		% of Total	1.9%	.0%	.0%	.0%	1.9%
Total		Count	1	2	21	29	53
		Expected Count	1.0	2.0	21.0	29.0	53.0
		% within BCLC Stage	100.0%	100.0%	100.0%	100.0%	100.0%
		% of Total	1.9%	3.8%	39.6%	54.7%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	66.389[a]	15	.000
Likelihood Ratio	24.882	15	.052
Linear-by-Linear Association	15.864	1	.000
N of Valid Cases	53		

a. 20 cells (83.3%) have expected count less than 5. The minimum expected count is .02.

SR.gab * BCLC Stage Crosstabulation

			BCLC Stage		
			A/B/C	D	Total
SR.gab	1	Count	10	24	34
		Expected Count	15.4	18.6	34.0
		% within BCLC Stage	41.7%	82.8%	64.2%
		% of Total	18.9%	45.3%	64.2%
	> 1	Count	14	5	19
		Expected Count	8.6	10.4	19.0
		% within BCLC Stage	58.3%	17.2%	35.8%
		% of Total	26.4%	9.4%	35.8%
Total		Count	24	29	53
		Expected Count	24.0	29.0	53.0
		% within BCLC Stage	100.0%	100.0%	100.0%
		% of Total	45.3%	54.7%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	9.642[b]	1	.002		
Continuity Correction[a]	7.938	1	.005		
Likelihood Ratio	9.906	1	.002		
Fisher's Exact Test				.004	.002
Linear-by-Linear Association	9.460	1	.002		
N of Valid Cases	53				

a. Computed only for a 2x2 table

b. 0 cells (.0%) have expected count less than 5. The minimum expected count is 8.60.

Survival Rate * Klasifikasi Child-Pugh Crosstabulation

			Klasifikasi Child-Pugh			
			A	B	C	Total
Survival Rate	1	Count	3	12	24	39
		Expected Count	5.9	13.9	19.2	39.0
		% within Klasifikasi Child-Pugh	33.3%	57.1%	82.8%	66.1%
		% of Total	5.1%	20.3%	40.7%	66.1%
	2	Count	5	4	4	13
		Expected Count	2.0	4.6	6.4	13.0
		% within Klasifikasi Child-Pugh	55.6%	19.0%	13.8%	22.0%
		% of Total	8.5%	6.8%	6.8%	22.0%
	3	Count	1	1	0	2
		Expected Count	.3	.7	1.0	2.0
		% within Klasifikasi Child-Pugh	11.1%	4.8%	.0%	3.4%
		% of Total	1.7%	1.7%	.0%	3.4%
	4	Count	0	3	0	3
		Expected Count	.5	1.1	1.5	3.0
		% within Klasifikasi Child-Pugh	.0%	14.3%	.0%	5.1%
		% of Total	.0%	5.1%	.0%	5.1%
	6	Count	0	0	1	1
		Expected Count	.2	.4	.5	1.0
		% within Klasifikasi Child-Pugh	.0%	.0%	3.4%	1.7%
		% of Total	.0%	.0%	1.7%	1.7%
	24	Count	0	1	0	1
		Expected Count	.2	.4	.5	1.0
		% within Klasifikasi Child-Pugh	.0%	4.8%	.0%	1.7%
		% of Total	.0%	1.7%	.0%	1.7%
Total		Count	9	21	29	59
		Expected Count	9.0	21.0	29.0	59.0
		% within Klasifikasi Child-Pugh	100.0%	100.0%	100.0%	100.0%
		% of Total	15.3%	35.6%	49.2%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	19.458[a]	10	.035
Likelihood Ratio	20.258	10	.027
Linear-by-Linear Association	.894	1	.344
N of Valid Cases	59		

a. 14 cells (77.8%) have expected count less than 5. The minimum expected count is .15.

Crosstabs

SR.gab * Klasifikasi Child-Pugh Crosstabulation

			Klasifikasi Child-Pugh			
			A	B	C	Total
SR. gab	1	Count	3	12	24	39
		Expected Count	5.9	13.9	19.2	39.0
		% within Klasifikasi Child-Pugh	33.3%	57.1%	82.8%	66.1%
		% of Total	5.1%	20.3%	40.7%	66.1%
	> 1	Count	6	9	5	20
		Expected Count	3.1	7.1	9.8	20.0
		% within Klasifikasi Child-Pugh	66.7%	42.9%	17.2%	33.9%
		% of Total	10.2%	15.3%	8.5%	33.9%
Total		Count	9	21	29	59
		Expected Count	9.0	21.0	29.0	59.0
		% within Klasifikasi Child-Pugh	100.0%	100.0%	100.0%	100.0%
		% of Total	15.3%	35.6%	49.2%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	8.656[a]	2	.013
Likelihood Ratio	8.761	2	.013
Linear-by-Linear Association	8.505	1	.004
N of Valid Cases	59		

a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 3.05.

HBV * HCV Crosstabulation

			HCV		
			Ya	Tidak	Total
HBV	Ya	Count	6	151	157
		Expected Count	10.7	146.3	157.0
		% within HCV	37.5%	68.9%	66.8%
		% of Total	2.6%	64.3%	66.8%
	Tidak	Count	10	68	78
		Expected Count	5.3	72.7	78.0
		% within HCV	62.5%	31.1%	33.2%
		% of Total	4.3%	28.9%	33.2%
Total		Count	16	219	235
		Expected Count	16.0	219.0	235.0
		% within HCV	100.0%	100.0%	100.0%
		% of Total	6.8%	93.2%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	6.651[b]	1	.010		
Continuity Correction[a]	5.308	1	.021		
Likelihood Ratio	6.186	1	.013		
Fisher's Exact Test				.014	.013
Linear-by-Linear Association	6.622	1	.010		
N of Valid Cases	235				

a. Computed only for a 2x2 table

b. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5. 31.

Crosstab

			Status		
			Hidup	Meninggal	Total
BCLC Stage	A	Count	2	1	3
		Expected Count	2.0	1.0	3.0
		% within Status	1.8%	1.9%	1.8%
		% of Total	1.2%	.6%	1.8%
	B	Count	18	2	20
		Expected Count	13.5	6.5	20.0
		% within Status	16.2%	3.8%	12.2%
		% of Total	11.0%	1.2%	12.2%
	C	Count	52	21	73
		Expected Count	49.4	23.6	73.0
		% within Status	46.8%	39.6%	44.5%
		% of Total	31.7%	12.8%	44.5%
	D	Count	39	29	68
		Expected Count	46.0	22.0	68.0
		% within Status	35.1%	54.7%	41.5%
		% of Total	23.8%	17.7%	41.5%
Total		Count	111	53	164
		Expected Count	111.0	53.0	164.0
		% within Status	100.0%	100.0%	100.0%
		% of Total	67.7%	32.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	8.293[a]	3	.040
Likelihood Ratio	9.167	3	.027
Linear-by-Linear Association	6.648	1	.010
N of Valid Cases	164		

a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is .97.

Klasifikasi Child-Pugh * Status

Crosstab

			Status		
			Hidup	Meninggal	Total
Klasifikasi Child-Pugh	A	Count	24	9	33
		Expected Count	23.1	9.9	33.0
		% within Status	17.5%	15.3%	16.8%
		% of Total	12.2%	4.6%	16.8%
	B	Count	75	21	96
		Expected Count	67.1	28.9	96.0
		% within Status	54.7%	35.6%	49.0%
		% of Total	38.3%	10.7%	49.0%
	C	Count	38	29	67
		Expected Count	46.8	20.2	67.0
		% within Status	27.7%	49.2%	34.2%
		% of Total	19.4%	14.8%	34.2%
Total		Count	137	59	196
		Expected Count	137.0	59.0	196.0
		% within Status	100.0%	100.0%	100.0%
		% of Total	69.9%	30.1%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	8.747[a]	2	.013
Likelihood Ratio	8.593	2	.014
Linear-by-Linear Association	4.792	1	.029
N of Valid Cases	196		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.93.

BCLC Stage * Status Crosstabulation

			Status		
			Hidup	Meninggal	Total
BCLC Stage	A/B	Count	20	3	23
		Expected Count	15.6	7.4	23.0
		% within Status	18.0%	5.7%	14.0%
		% of Total	12.2%	1.8%	14.0%
	C	Count	52	21	73
		Expected Count	49.4	23.6	73.0
		% within Status	46.8%	39.6%	44.5%
		% of Total	31.7%	12.8%	44.5%
	D	Count	39	29	68
		Expected Count	46.0	22.0	68.0
		% within Status	35.1%	54.7%	41.5%
		% of Total	23.8%	17.7%	41.5%
Total		Count	111	53	164
		Expected Count	111.0	53.0	164.0
		% within Status	100.0%	100.0%	100.0%
		% of Total	67.7%	32.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	7.644[a]	2	.022
Likelihood Ratio	8.178	2	.017
Linear-by-Linear Association	7.584	1	.006
N of Valid Cases	164		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.43.

Status * Tahun Crosstabulation

			Tahun			
			2010	2011	2012	Total
Status	Hidup	Count	59	64	49	172
		Expected Count	60.0	61.5	50.5	172.0
		% within Tahun	72.0%	76.2%	71.0%	73.2%
		% of Total	25.1%	27.2%	20.9%	73.2%
	Meninggal	Count	23	20	20	63
		Expected Count	22.0	22.5	18.5	63.0
		% within Tahun	28.0%	23.8%	29.0%	26.8%
		% of Total	9.8%	8.5%	8.5%	26.8%
Total		Count	82	84	69	235
		Expected Count	82.0	84.0	69.0	235.0
		% within Tahun	100.0%	100.0%	100.0%	100.0%
		% of Total	34.9%	35.7%	29.4%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	.616[a]	2	.735
Likelihood Ratio	.622	2	.733
Linear-by-Linear Association	.008	1	.929
N of Valid Cases	235		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 18.50.

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Bilirubin Total	.255	182	.000	.630	182	.000
Albumin serum	.070	182	.030	.992	182	.398
PPT	.210	182	.000	.619	182	.000

a. Lilliefors Significance Correction

Means

Survival Rate * BCLC Stage

Survival Rate

BCLC Stage	Mean	N	Std. Deviation	Median	Minimum	Maximum
A	24.00	1	.	24.00	24	24
B	1.50	2	.707	1.50	1	2
C	1.86	21	.964	2.00	1	4
D	1.31	29	.967	1.00	1	6
Total	1.96	53	3.234	1.00	1	24

Survival Rate * Klasifikasi Child-Pugh

Survival Rate

Klasifikasi Child-Pugh	Mean	N	Std. Deviation	Median	Minimum	Maximum
A	1.78	9	.667	2.00	1	3
B	2.81	21	4.976	1.00	1	24
C	1.31	29	.967	1.00	1	6
Total	1.92	59	3.087	1.00	1	24

Lampiran 2

KOMISI ETIK PENELITIAN KESEHATAN (KEPK)
FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO
DAN RSUP dr KARIADI SEMARANG
Sekretariat : Kantor Dekanat FK Undip Lt.3
Jl. Dr. Soetomo 18. Semarang 50231
Telp/Fax. 024-8318350

RSUP Dr. KARIADI

ETHICAL CLEARANCE

No.213 /EC/FK-RSDK/2014

Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro/ RSUP Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian dengan judul :

KARAKTERISTIK KLINIS PAIEN KARSINOMA HEPATOSELULER :
(Studi kasus di RSUP Dr. Kariadi semarang Periode 2010-1012)

Peneliti Utama	:	Intan Ayuningtyas
Pembimbing	:	Dr. dr. Hery Djagat Purnomo, Sp.PD-KGEH
Penelitian	:	Dilaksanakan di RSUP Dr. Kariadi Semarang

Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011

Peneliti harus melampirkan 2 kopi lembar Informed consent yang telah disetujui dan ditandatangani oleh peserta penelitian pada laporan penelitian.
Peneliti diwajibkan menyerahkan :
- Laporan kemajuan penelitian (clinical Trial)
- Laporan kejadian efek samping jika ada dan dijaga kerahasiaan subyek
- Laporan ke KEPK jika penelitian sudah selesai & dilampiri Abstrak Penelitian.

Semarang, 02 MAY 2014

Komisi Etik Penelitian Kesehatan
Fakultas Kedokteran Undip/RSUP Dr. Kariadi
Ketua

KOMISI ETIK PENELITIAN KESEHATAN SEMARANG KEPK FK. UNDIP RS. Dr. KARIADI

Prof.Dr.dr.Suprihati, M.Sc, Sp.THT-KL(K)
NIP. 19500621197703 2 001

Lampiran 3

KEMENTERIAN KESEHATAN RI
DIREKTORAT JENDERAL BINA UPAYA KESEHATAN
RUMAH SAKIT UMUM PUSAT DOKTER KARIADI
Jalan Dr. Sutomo No. 16 Semarang, PO BOX 1104
Telepon : (024) 8413993, 8413476, 8413764 Fax : (024) 8318617
Website : http://www.rskariadi.com email : rsdk@indosat.net.id ; rsdk@rskariadi.com

RSUP Dr. KARIADI
Sahabat Menuju Sehat

SURAT IZIN
MELAKSANAKAN PENELITIAN

DL.00.02 / I.II / 1315 / 2014

Yang bertanda tangan di bawah ini :

Nama	:	Dr. Agus Suryanto, Sp.PD-KP, MARS
N I P	:	19610818 198812 1001
Jabatan	:	Direktur SDM dan Pendidikan RSUP Dr. Kariadi

Memberikan ijin melakukan penelitian untuk :

Nama peneliti	:	Intan Ayuningtyas
Institusi peneliti	:	Universitas Diponegoro (Fakultas Kedokteran)
Judul penelitian	:	Karakteristik Klinis Pasien Karsinoma Hepatoseluler: Studi Kasus Di RSUP DR Kariadi Semarang Periode 2010-2012
Pembimbing	:	Dr. dr. Hery Djagat Purnomo, Sp.PD-KGEH
DPJP	:	–
Lokasi penelitian	:	Instalasi Rekam Medis

untuk melaksanakan kegiatan penelitian selama ±1 bulan.

Peneliti wajib melakukan :
1. Laporan monitoring evaluasi penelitian secara periodik
2. Laporan selesai penelitian dengan menyerahkan monitoring evaluasi penelitian
3. Menyerahkan laporan hasil akhir penelitian (1 berkas)

Semarang, 21 MAY 2014
An. Direktur Utama
Direktur SDM dan Pendidikan

RSUP Dr. KARIADI

Dr. Agus Suryanto, Sp.PD-KP, MARS
NIP. 19610818 198812 1 001

Lampiran 4

KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS DIPONEGORO
FAKULTAS KEDOKTERAN
Jl. Prof. H. Soedarto, SH – Tembalang – Semarang
Telepon 024-76928010, Fax. 024-76928011, Email : dean_fmdu@undip.ac.id

Nomor : 1712 /UN7.3.4/D1/PP/2014
Lampiran : 1 bendel
Perihal : Permohonan ijin penelitian

26 MAR 2014

Yth. Direktur Utama
RSUP Dr. Kariadi
Semarang

Dengan hormat,

Bersama ini kami hadapkan mahasiswa Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Diponegoro Semarang :

Nama : Intan Ayuningtyas
NIM : 22010110110093
Semester : VIII (delapan)

Mohon diijinkan melakukan penelitian di RSUP Dr. Kariadi Semarang, dalam rangka penyusunan Karya Tulis Ilmiah mahasiswa. Terlampir proposal mahasiswa yang bersangkutan.

Judul/ Topik : Karakteristik Klinis Pasien Karsinoma Hepatoseluler: Studi Kasus di RSUP Dr. Kariadi Semarang Periode 2010-2012

Pembimbing : Dr. dr. Hery Djagat Purnomo, Sp.PD-KGEH

Atas perhatian dan kerjasamanya diucapkan terima kasih.

a.n Dekan
Pembantu Dekan I,

dr. Herman Kristanto, MS, Sp.OG(K)
NIP. 196305051989031003

Tembusan :
1. Dekan (sebagai laporan)
2. Ketua Tim Karya Tulis Ilmiah
3. Kepala Bagian Diklit RSUP Dr. Kariadi Semarang
4. Pembimbing
5. Mahasiswa Yang Bersangkutan

Lampiran 5

BIODATA

Identitas

Nama	: Intan Ayuningtyas
NIM	: 22010110110093
Tempat/Tanggal lahir	: Tegal/3 Oktober 1992
Jenis Kelamin	: Perempuan
Alamat	: Jalan Dr. Cipto Mangunkusumo no. 109 Tegal
Nomor Telepon	: (0283) 357481
Nomor HP	: 081326810414
Email	: intan.093@gmail.com

Riwayat Pendidikan Formal

1.	SD	: SD Negeri Mangkukusuman 8 Tegal	Lulus Tahun: 2004
2.	SMP	: SMP Negeri 2 Tegal	Lulus Tahun: 2007
3.	SMA	: SMA Negeri 1 Tegal	Lulus Tahun: 2010
4.	FK UNDIP	: Masuk Tahun: 2010	